Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.73 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.02M
Market Cap
$2.13B
Enterprise Value$2.15B
Total Cash (Recent Filing)$287.36M
Total Debt (Recent Filing)$50.50M
Price to Earnings (P/E)64.7
Beta1.65
Next Earnings
Jul 30, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding78,314,610
10 Day Avg. Volume1,002,403
30 Day Avg. Volume1,017,380
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)1.91
Price to Sales (P/S)0.00
P/FCF Ratio29.14
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit6.87
Enterprise Value/Ebitda27.22
Forecast
1Y Price Target
$39.67Price Target Upside41.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Veracyte News
PremiumCompany Announcements
Veracyte Inc. Reports Strong Q1 2025 Earnings
PremiumCompany Announcements
Veracyte Reports Strong Q1 2025 Financial Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTotal revenues were ahead of consensus at $114M, and management increased expected EBITDA margins, underscoring commitment to profitable growth.
Market ExpansionThe announcement of launching Prosigna as an LDT in the United States by mid-2026 indicates strategic expansion and potential growth.
Product DevelopmentVCYT has built strong clinical evidence that fuels adoption of its core Decipher (prostate) and Afirma (thyroid) tests, and is working to build their pipeline of assays.
Bears Say
Market CompetitionProsigna LDT launch promising but enters a competitive market.
Operational ChallengesThe strategic review of the French subsidiary could potentially delay IVD timelines.
Revenue DeclineProduct revenue experienced a year-over-year decline of 18%, impacted by ongoing supply chain issues affecting Prosigna nCounter.
Ownership Overview
1.43% Insiders
34.47% Mutual Funds
1.58% Other Institutional Investors
36.35% Public Companies and Individual Investors
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $19.73 and its highest was $47.32 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.13B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Jul 30, 2025 which is in 63 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on May 07, 2025. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.064.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.11.
How many shares outstanding does Veracyte have?
Veracyte has 78,314,610 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.09 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went up 1.2%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.67 (41.83% Upside)
$39.67 (41.83% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 87.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $460.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.32%
12-Months-Change
Fundamentals
Return on Equity
2.86%
Trailing 12-Months
Asset Growth
9.61%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance with significant revenue growth, particularly in the Decipher and Afirma tests, and positive developments in upcoming product launches. However, challenges with the SAS subsidiary and some revenue impacts due to prior period collections and tariffs present potential hurdles.Read More>VCYT Stock 12 Month Forecast
Average Price Target
$39.67
▲(41.83%Upside)